Wednesday, March 25, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Many pharmacies refusing to give fourth shots to immune-compromised patients

The US Centers for Disease Control and Prevention plans to send a clear message to pharmacies on a conference call this week: Stop turning away immune-compromised people when they come seeking fourth doses of Covid-19 vaccines.

Although fourth doses are not currently recommended for the vast majority of Americans, the CDC has urged millions of people with compromised immune systems to get them.

But many immune-compromised people tell CNN that pharmacies and hospitals have refused to give them fourth doses, leaving those most vulnerable to the virus without the protection the CDC wants them to have.

“A lot of pharmacies are just not understanding. They hear ‘fourth shot,’ and it just freaks them out,” said Elizabeth Nunn, who is immune-compromised and was turned away for a fourth shot by three pharmacies near her home north of New York City.

Source: CNN

https://www.cnn.com/2022/01/26/health/fourth-shots-immune-compromised/index.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!